 COPENHAGEN, Denmark, August 23, 2021 Bavarian Nordic AS OMX: BAVA announced today that the Company has entered a funding agreement with the Danish Ministry of Health to further advance the development of ABNCoV2, the Companys COVID-19 vaccine candidate. 